Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ) K% Y; @* N. ^4 W7 {
H7 ^: @2 Z _2 l2 `0 d- A( \! D# }/ d. n b
Sub-category:$ K, o/ A/ k4 c4 M
Molecular Targets
; ?3 z2 U, V' U5 P
8 G2 A9 q" {8 ~1 Z! V8 e1 Q4 d U- x9 N9 S
Category:
: ~. F1 |; r6 I9 [/ ]( W/ R) cTumor Biology
, D$ w5 S, p: k0 {- t: \6 t7 l' m; i/ {4 }& q! p! s( p" k; ?
* {- r: l) R, W6 W1 [Meeting:
$ a. l `( n& Q# t* O2011 ASCO Annual Meeting ) x8 E2 g: ?. g8 ?( \
/ n4 }; {" w% z3 u \5 |, Z e7 \; _7 {
0 H) Q0 y3 @6 l" s N- F7 B" sSession Type and Session Title:$ Y5 J) p# X8 d( J( H# _% k6 r- ]
Poster Discussion Session, Tumor Biology
; i Q+ ^9 o4 H6 F0 S$ r, t) {6 u. ]: _) B
0 j% ^2 O. M _/ G: Z3 j2 b; z
Abstract No:& w+ m" v; Z$ l" H
10517 4 Z1 [5 ?7 a/ u! G g* t
& p0 F( ^; s) _4 A5 X
3 l: D# M+ l$ jCitation:1 r$ t; {. G. }9 t- _
J Clin Oncol 29: 2011 (suppl; abstr 10517)
$ L; k7 | K, E. r) e: A
* J/ o: j" Y0 Q1 U2 n( S7 A4 a
9 t' L8 a0 @) u& f, o0 P4 @Author(s): p Q, h, a7 w) @# G
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
+ t2 R& L2 a: z# u9 N! U9 S8 P& V( D% P' j
5 `+ s. ?5 f6 B; \: G8 R' \
' \0 Z* Y$ E1 k" U" b
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.) c/ W8 @& i2 P; a9 c
" e, o" t; h2 U* ]3 j, m
Abstract Disclosures
7 }+ C; N6 _! z0 h7 x6 `4 t8 l3 N' u* x6 ], Y F. H
Abstract:
4 q' @# t" e7 `7 Y$ o
[4 p7 U/ e! Q1 V
) \0 @2 g1 q {! FBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
% a; I6 L: T. Y* K7 `4 P; o: L w2 _+ ]8 i" g
* J8 H$ T8 I) K+ a5 d: A- g5 o |